Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
86
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation

Guanyu Li1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China
,
Tong Wang1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China
,
Xiaoyi Zhang1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China
,
Shurui Zhao1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China
,
Yaonan Wang1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-2159-2730
ORCID Icon,
Jianhui Wu1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9416-8952
ORCID Icon,
Shiqi Peng1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-2669-6715
ORCID Icon &
Ming Zhao1 Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;2 Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China;3 Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, People’s Republic of China
 show all
Pages 2187-2197 | Published online: 03 Jun 2020

References

  • WangN, TanH-Y, LiL, YuenM-F, FengY. Berberine and coptidis rhizoma as potential anticancer agents: recent updates and future perspectives: recent updates and future perspectives. J Ethnopharmacol. 2015;176:35–48. doi:10.1016/j.jep.2015.10.02826494507
  • Yang-S-S, YuC-B, LuoZ, et al. Berberine attenuates sodium palmitate-induced lipid accumulation, oxidative stress and apoptosis in grass carp(Ctenopharyngodon idella)hepatocyte in vitro. Fish Shellfish Immunol. 2019;88:518–527. doi:10.1016/j.fsi.2019.02.05530880233
  • RenK, ZhangW, WuG, et al. Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells. Biomed Pharmacother. 2016;84:1748–1759. doi:10.1016/j.biopha.2016.10.11127876206
  • HuS, ChenC-W, ChenS-T, et al. Inhibitory effect of berberine on interleukin-2 secretion from PHA-treated lymphocytic jurkat cells. Int Immunopharmacol. 2019;66:267–273. doi:10.1016/j.intimp.2018.11.02030502647
  • ChangY-P, HuangC-C, ShenC-C, et al. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab Pharmacokinet. 2015;30(5):374–383. doi:10.1016/j.dmpk.2015.08.00626403084
  • NaveenCR, GaikwadS, Agrawal-RajputR. Berberine induces neuronal differentiation through inhibition of cancer stemness and epithelial-mesenchymal transition in neuroblastoma cells. Phytomedicine. 2016;23(7):736–744. doi:10.1016/j.phymed.2016.03.01327235712
  • SteinDJ, KhooJ-P, AhokasA, et al. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder. Eur Neuropsychopharm. 2018;28(8):970–979. doi:10.1016/j.euroneuro.2018.05.006
  • KumarA, ChopraK, MukherjeeM, PottabathiniR, DhullDK. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. 2015;761:288–297. doi:10.1016/j.ejphar.2015.05.06826092760
  • YuY, HaoG, ZhangQ, et al. Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochem Pharmacol. 2015;97(2):173–177. doi:10.1016/j.bcp.2015.07.01226206195
  • LangS, PoppT, KriegsCS, et al. Anti-apoptotic and moderate anti-inflammatory effects of berberine in sulfur mustard exposed keratinocytes. Toxicol Lett. 2017;293:2–8. doi:10.1016/j.toxlet.2017.09.00428916288
  • LuganiniA, MercorelliB, MessaL, PalùG, GribaudoG, LoregianA. The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity. Antiviral Res. 2019;164:52–60. doi:10.1016/j.antiviral.2019.02.00630738836
  • Hashemi-NiasariF, Rabbani-ChadeganiA, RazmiM, FallahS. Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells. Biomed Pharmacother. 2018;106:858–867. doi:10.1016/j.biopha.2018.07.01930119256
  • ZhangH, ShanY, WuY, et al. Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-κB signaling pathway in RAW264.7 cells. Int Immunopharmacol. 2017;52:93–100. doi:10.1016/j.intimp.2017.08.03228888780
  • WangY, ZhangS. Berberine suppresses growth and metastasis of endometrial cancer cells via miR-101/COX-2. Biomed Pharmacother. 2018;103:1287–1293. doi:10.1016/j.biopha.2018.04.16129864910
  • TsangCM, Pan CheungKC, CheungYC, et al. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 2015;1852(3):541–551. doi:10.1016/j.bbadis.2014.12.00425496992
  • LiY-H, XiaoH-T, HuD-D, et al. Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses. Pharmacol Res. 2016;110:227–239. doi:10.1016/j.phrs.2016.02.01026969793
  • LiJ-W, YuanK, ShangS-C, GuoY. A safer hypoglycemic agent for type 2 diabetes—berberine organic acid salt. J Funct Foods. 2017;38(Pt A):399–408. doi:10.1016/j.jff.2017.09.031
  • WongSK, ChinK-Y, Ima-NirwanaS. Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. Phytomedicine. 2019;13:152892.
  • PopiołekI, NiziołekA, KamińskiK, KwolekU, NowakowskaM, KrzysztofS. Cellular delivery and enhanced anticancer activity of berberine complexed with a cationic derivative of γ –cyclodextrin. Bioorg Med Chem. 2019;27(7):1414–1420. doi:10.1016/j.bmc.2019.02.04230808605
  • Jiao HaoM, LiY, LiuL, et al. The design and synthesis of a novel compound of berberine and baicalein that inhibits the efficacy of lipid accumulation in 3T3-L1 adipocytes. Bioorg Med Chem. 2017;25(20):5506–5512. doi:10.1016/j.bmc.2017.08.01328818460
  • LiY-H, ZhangM, FuH-B, XiaoH-T, BianZ-X. Pre-clinical toxicity of a combination of berberine and 5-aminosalicylic acid in mice. Food Chem Toxicol. 2016;97:150–158. doi:10.1016/j.fct.2016.08.03127587080
  • GuptaL, SharmaAK, GothwalA, et al. Dendrimer encapsulated and conjugated delivery of berberine: a novel approach mitigating toxicity and improving in vivo pharmacokinetics. Int J Pharm. 2017;528(1–2):88–99. doi:10.1016/j.ijpharm.2017.04.07328533175
  • LiG, RenY, ZhangX, et al. 13-[CH2CO-Cys-(Bal)-OBzl]-berberine: exploring the correlation of anti-tumor efficacy with ROS and apoptosis protein. Onco Targets Ther. 2019;12:10651–10662. doi:10.2147/OTT.S23103531824172
  • LiuW, MaoY, ZhangX, et al. RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine. Int J Nanomedicine. 2019;14:7263–7279. doi:10.2147/IJN.S21297831686807
  • SulemanA, JarvisV, HadziomerovicA, CarrierM, McDiarmidS. Implanted vascular access device related deep vein thrombosis in oncology patients: a prospective cohort study. Thromb Res. 2019;177:117–121. doi:10.1016/j.thromres.2019.02.03330875491
  • ChenH, LuA, ZhangX, et al. Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors. Drug Des Devel Ther. 2018;12:2097–2110. doi:10.2147/DDDT.S169238
  • OtaniK, IshiharaS, HataK, et al. Colorectal cancer with venous tumor thrombosis. Asian J Surg. 2018;41(3):197–202. doi:10.1016/j.asjsur.2016.07.01327693064
  • LiuS, ZhangF, XieL, et al. Machine learning approaches for risk assessment of peripherally inserted central catheter-related vein thrombosis in hospitalized patients with cancer. Int J Med Inform. 2019;129:175–183. doi:10.1016/j.ijmedinf.2019.06.00131445252
  • FargeD, Le MaignanC, DoucetL, FrereC. Women, thrombosis, and cancer. Thromb Res. 2019;181(Suppl 1):S47–S53. doi:10.1016/S0049-3848(19)30367-631477228
  • LeeJ, JackmanJG, KwunJ, et al. Nucleic acid scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. Biomaterials. 2017;120:94–102. doi:10.1016/j.biomaterials.2016.12.02428049065
  • AmaniH, HabibeyR, ShokriF, et al. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Sci Rep. 2019;9(1):6044. doi:10.1038/s41598-019-42633-930988361

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.